Transatlantique Private Wealth LLC Buys 776 Shares of McKesson Co. (NYSE:MCK)

Transatlantique Private Wealth LLC grew its stake in McKesson Co. (NYSE:MCK - Free Report) by 32.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,145 shares of the company's stock after acquiring an additional 776 shares during the period. Transatlantique Private Wealth LLC's holdings in McKesson were worth $1,792,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of MCK. Norges Bank acquired a new position in McKesson in the fourth quarter valued at approximately $1,200,361,000. Marshall Wace LLP raised its position in shares of McKesson by 59,720.3% during the 4th quarter. Marshall Wace LLP now owns 358,922 shares of the company's stock valued at $204,553,000 after acquiring an additional 358,322 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of McKesson in the 4th quarter valued at $178,397,000. Alliancebernstein L.P. boosted its position in shares of McKesson by 46.6% in the 4th quarter. Alliancebernstein L.P. now owns 855,332 shares of the company's stock worth $487,462,000 after purchasing an additional 272,068 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of McKesson during the fourth quarter worth $128,125,000. 85.07% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Leann B. Smith sold 188 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total value of $114,602.92. Following the completion of the transaction, the executive vice president now owns 1,051 shares of the company's stock, valued at $640,679.09. This represents a 15.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Brian S. Tyler sold 8,961 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $597.99, for a total value of $5,358,588.39. Following the completion of the sale, the chief executive officer now owns 60,664 shares in the company, valued at $36,276,465.36. This trade represents a 12.87 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,110 shares of company stock worth $10,855,706. Insiders own 0.11% of the company's stock.

McKesson Trading Down 0.6 %

Shares of NYSE:MCK traded down $4.01 during trading on Thursday, reaching $688.26. 862,210 shares of the stock were exchanged, compared to its average volume of 890,505. The stock has a 50-day moving average price of $657.47 and a 200-day moving average price of $603.65. The firm has a market cap of $86.26 billion, a PE ratio of 31.51, a PEG ratio of 1.29 and a beta of 0.49. McKesson Co. has a 12 month low of $464.42 and a 12 month high of $728.32.

McKesson (NYSE:MCK - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. On average, sell-side analysts expect that McKesson Co. will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd were issued a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, March 3rd. This represents a $2.84 annualized dividend and a dividend yield of 0.41%. McKesson's dividend payout ratio (DPR) is presently 13.00%.

Analyst Ratings Changes

A number of equities analysts have issued reports on MCK shares. Citigroup reduced their target price on McKesson from $713.00 to $677.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Evercore ISI upped their target price on shares of McKesson from $650.00 to $675.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Cfra Research cut shares of McKesson from a "moderate buy" rating to a "hold" rating in a research report on Friday, April 4th. Mizuho upped their price objective on shares of McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a research report on Thursday, April 3rd. Finally, StockNews.com downgraded McKesson from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, McKesson has an average rating of "Moderate Buy" and a consensus price target of $668.50.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.